The role of iron in the pathogenesis of experimental allergic encephalomyelitis and multiple sclerosis

Annals of the New York Academy of Sciences

Volumn 1012, Issue , 2004, Pages 252-266

  LeVine, Steven M ^a   Chakrabarty, Anuradha ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Experimental allergic encephalomyelitis; Ferritin; Heme oxygenase; Iron; Multiple sclerosis; Myelin; Oligodendrocyte; Oxidative damage; Transferrin

Indexed keywords

DEFEROXAMINE MESYLATE; FERRITIN; FREE RADICAL; HEME OXYGENASE 1; IRON; IRON BINDING PROTEIN; MYELIN; TRANSFERRIN;

ADULT; ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ASTROCYTE; AUTOIMMUNE DISEASE; BLOOD BRAIN BARRIER; CATALYST; CELL INFILTRATION; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; DEMYELINATION; GLIOSIS; HUMAN; IRON METABOLISM; MACROPHAGE; MICROGLIA; MOUSE; MULTIPLE SCLEROSIS; NERVE FIBER TRANSECTION; NONHUMAN; OLIGODENDROGLIA; PATHOGENESIS; PROTEIN LOCALIZATION; REVIEW; T LYMPHOCYTE;

ANIMALIA;

EID: 1842556542     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1306.021     Document Type: Review

References (126)

1. MORELL, P., R.H. QUARLES & W.T. NORTON. 1993. Myelin formation, structure, and biochemistry. In Basic Neurochemistry, pp. 117-143. Raven Press. New York.
2. NGUYEN-LEGROS, J., J. BIZOT, M. BOLESSE & J.P. PULICANI. 1980. "Diaminobenzidine black" as a new histochemical demonstration of exogenous iron. Histochemistry 66: 239-244.
3. LEVINE, S.M. & W.B. MACKLIN. 1990. Iron-enriched oligodendrocytes: a reexamination of their spatial distribution. J. Neurosci. Res. 26: 508-512.
4. LEVINE, S.M. 1991. Oligodendrocytes and myelin sheaths in normal, quaking, and shiverer brains are enriched in iron. J. Neurosci. Res. 29: 413-419.
5. SMITH, M.A., P.L. HARRIS, L.M. SAYRE & G. PERRY. 1997. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. USA 94: 9866-9868.
6. FRANCOIS, C., J. NGUYEN-LEGROS & G. PERCHERON. 1981. Topographical and cytological localization of iron in rat and monkey brains. Brain Res. 215: 317-322.
7. HILL, J.M. & R.C. SWITZER III. 1984. The regional distribution and cellular localization of iron in the rat brain. Neuroscience 11: 595-603.
8. HILL, J.M., M.R. RUFF, R.J. WEBER & C.B. PERT. 1985. Transferrin receptors in rat brain: neuropeptide-like pattern and relationship to iron distribution. Proc. Natl. Acad. Sci. USA 82: 4553-4557.
9. DWORK, A.J., E.A. SCHON & J. HERBERT. 1988. Nonidentical distribution of transferrin and ferric iron in human brain. Neuroscience 27: 333-345.
10. GERBER, M.R. & J.R. CONNOR. 1989. Do oligodendrocytes mediate iron regulation in the human brain? Ann. Neurol. 26: 95-98.
11. CONNOR, J.R. & S.L. MENZIES. 1990. Altered cellular distribution of iron in the central nervous system of myelin deficient rats. Neuroscience 34: 265-271.
12. CONNOR, J.R., S.L. MENZIES, S.M. ST. MARTIN & E.J. MUFSON. 1990. Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains. J. Neurosci. Res. 27: 595-611.
13. RAJAN, K.S., R.W. COLBURN & J.M. DAVIS. 1976. Distribution of metal ions in the subcellular fractions of several rat brain areas. Life Sci. 18: 423-431.
14. CONNOR, J.R., G. PAVLICK, D. KARLI et al. 1995. A histochemical study of iron-positive cells in the developing rat brain. J. Comp. Neurol. 355: 111-123.
15. ERB, G.L., D.L. OSTERBUR & S.M. LEVINE. 1996. The distribution of iron in the brain: a phylogenetic analysis using iron histochemistry. Brain Res. Dev. Brain Res. 93: 120-128.
16. YU, G.S., T.M. STEINKIRCHNER, G.A. RAO & E.C. LARKIN. 1986. Effect of prenatal iron deficiency on myelination in rat pups. Am. J. Pathol. 125: 620-624.
17. BEARD, J.L., J.A. WIESINGER & J.R. CONNOR. 2003. Pre-and postweaning iron deficiency alters myelination in Sprague-Dawley rats. Dev. Neurosci. 25: 308-315.
18. BLOCH, B., T. POPOVICI, M.J. LEVIN et al. 1985. Transferrin gene expression visualized in oligodendrocytes of the rat brain by using in situ hybridization and immunohistochemistry. Proc. Natl. Acad. Sci. USA 82: 6706-6710.
19. CONNOR, J.R. & R.E. FINE. 1987. Development of transferrin-positive oligodendrocytes in the rat central nervous system. J. Neurosci. Res. 17: 51-59.
20. URBAN, K., M. HEWICKER-TRAUTWEIN & G. TRAUTWEIN. 1998. Immunohistochemical localization of transferrin in the pre-and postnatal bovine brain. Anat. Histol. Embryol. 27: 45-49.
21. ESPINOSA DE LOS MONTEROS, A., L. PENA & J. DE VELLIS. 1989. Does transferrin have a special role in the nervous system? J. Neurosci. Res. 24: 125-136.
22. ESPINOSA DE LOS MONTEROS, A., S. KUMAR, S. SCULLY et al. 1990. Transferrin gene expression and secretion by rat brain cells in vitro. J. Neurosci. Res. 25: 576-580.
23. DE ARRIBA ZERPA, G.A., M.C. SALEH, P.M. FERNANDEZ et al. 2000. Alternative splicing prevents transferrin secretion during differentiation of a human oligodendrocyte cell line. J. Neurosci. Res. 61: 388-395.
24. CONNOR, J.R. & S.L. MENZIES. 1996. Relationship of iron to oligodendrocytes and myelination. Glia 17: 83-93.
25. MOOS, T. 1996. Immunohistochemical localization of intraneuronal transferrin receptor immunoreactivity in the adult mouse central nervous system. J. Comp. Neurol. 375: 675-692.
26. DICKINSON, T.K. & J.R. CONNOR. 1998. Immunohistochemical analysis of transferrin receptor: regional and cellular distribution in the hypotransferrinemic (hpx) mouse brain. Brain Res. 801: 171-181.
27. TAKEDA, A., A. DEVENYI & J.R. CONNOR. 1998. Evidence for non-transferrin-mediated uptake and release of iron and manganese in glial cell cultures from hypotransferrinemic mice. J. Neurosci. Res. 51: 454-462.
28. MESCHER, A.L. & S.I. MUNAIM. 1988. Transferrin and the growth-promoting effect of nerves. Int. Rev. Cytol. 110: 1-26.
29. ESCOBAR CABRERA, O.E., E.R. BONGARZONE, E.F. SOTO & J.M. PASQUINI. 1994. Single intracerebral injection of apotransferrin in young rats induces increased myelination. Dev. Neurosci. 16: 248-254.
30. ESPINOSA DE LOS MONTEROS, A., S. KUMAR, P. ZHAO et al. 1999. Transferrin is an essential factor for myelination. Neurochem. Res. 24: 235-248.
31. MARTA, C.B., O.E. ESCOBAR CABRERA, C.I. GARCIA et al. 2000. Oligodendroglial cell differentiation in rat brain is accelerated by the intracranial injection of apotransferrin. Cell. Mol. Biol. (Noisy-Le-Grand) 46: 529-539.
32. HULET, S.W., E.J. HESS, W. DEBINSKI et al. 1999. Characterization and distribution of ferritin binding sites in the adult mouse brain. J. Neurochem. 72: 868-874.
33. HULET, S.W., S. POWERS & J.R. CONNOR. 1999. Distribution of transferrin and ferritin binding in normal and multiple sclerotic human brains. J. Neurol. Sci. 165: 48-55.
34. HULET, S.W., S.O. HEYLIGER, S. POWERS & J.R. CONNOR. 2000. Oligodendrocyte progenitor cells internalize ferritin via clathrin-dependent receptor mediated endocytosis. J. Neurosci. Res. 61: 52-60.
35. OZAWA, H., A. NISHIDA, T. MITO & S. TAKASHIMA. 1994. Development of ferritin-positive cells in cerebrum of human brain. Pediatr. Neurol. 10: 44-48.
36. IIDA, K., S. TAKASHIMA & K. UEDA. 1995. Immunohistochemical study of myelination and oligodendrocyte in infants with periventricular leukomalacia. Pediatr. Neurol. 13: 296-304.
37. CHEEPSUNTHORN, P., C. PALMER & J.R. CONNOR. 1998. Cellular distribution of ferritin subunits in postnatal rat brain. J. Comp. Neurol. 400: 73-86.
38. SANYAL, B., P.E. POLAK & S. SZUCHET. 1996. Differential expression of the heavy-chain ferritin gene in non-adhered and adhered oligodendrocytes. J. Neurosci. Res. 46: 187-197.
39. BLISSMAN, G., S. MENZIES, J. BEARD et al. 1996. The expression of ferritin subunits and iron in oligodendrocytes in neonatal porcine brains. Dev. Neurosci. 18: 274-281.
40. HAN, J., J.R. DAY, J.R. CONNOR & J.L. BEARD. 2002. H and L ferritin subunit mRNA expression differs in brains of control and iron-deficient rats. J. Nutr. 132: 2769-2774.
41. THOMPSON, K., S. MENZIES, M. MUCKENTHALER et al. 2003. Mouse brains deficient in H-ferritin have normal iron concentration, but a protein profile of iron deficiency and increased evidence of oxidative stress. J. Neurosci. Res. 71: 46-63.
42. DICKINSON, T.K. & J.R. CONNOR. 1995. Cellular distribution of iron, transferrin, and ferritin in the hypotransferrinemic (Hp) mouse brain. J. Comp. Neurol. 355: 67-80.
43. FORGE, J.K., T.V. PEDCHENKO & S.M. LEVINE. 1998. Iron deposits in the central nervous system of SJL mice with experimental allergic encephalomyelitis. Life Sci. 63: 2271-2284.
44. CRAELIUS, W., M.W. MIGDAL, C.P. LUESSENHOP et al. 1982. Iron deposits surrounding multiple sclerosis plaques. Arch. Pathol. Lab. Med. 106: 397-399.
45. WALTON, J.C. & J.C. KAUFMANN. 1984. Iron deposits and multiple sclerosis. Arch. Pathol. Lab. Med. 108: 755-756.
46. ADAMS, C.W. 1988. Perivascular iron deposition and other vascular damage in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 51: 260-265.
47. LEVINE, S.M. 1997. Iron deposits in multiple sclerosis and Alzheimer's disease brains. Brain Res. 760: 298-303.
48. ARNOLD, D.L., G.T. RIESS, P.M. MATTHEWS et al. 1994. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann. Neurol. 36: 76-82.
49. TRAPP, B.D., J. PETERSON, R.M. RANSOHOFF et al. 1998. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338: 278-285.
50. TRAPP, B.D., L. BO, S. MORK & A. CHANG. 1999. Pathogenesis of tissue injury in MS lesions. J. Neuroimmunol. 98: 49-56.
51. BJARTMAR, C., G. KIDD, S. MORK et al. 2000. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann. Neurol. 48: 893-901.
52. PETERSON, J.W., L. BO, S. MORK et al. 2001. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann. Neurol. 50: 389-400.
53. MEHINDATE, K., D.J. SAHLAS, D. FRANKEL et al. 2001. Proinflammatory cytokines promote glial heme oxygenase-1 expression and mitochondrial iron deposition: implications for multiple sclerosis. J. Neurochem. 77: 1386-1395.
54. QI, Y. & G. DAWSON. 1994. Hypoxia specifically and reversibly induces the synthesis of ferritin in oligodendrocytes and human oligodendrogliomas. J. Neurochem. 63: 1485-1490.
55. QI, Y., T.M. JAMINDAR & G. DAWSON. 1995. Hypoxia alters iron homeostasis and induces ferritin synthesis in oligodendrocytes. J. Neurochem. 64: 2458-2464.
56. CHAKRABARTY, A., M.R. EMERSON & S.M. LEVINE. 2003. Heme oxygenase-1 in SJL mice with experimental allergic encephalomyelitis. Mult. Scler. 9: 372-381.
57. BAARK, J.P., O. BERG & L. HEMMINGSEN. 1983. Immunonephelometric determination of proteins in cerebrospinal fluid in various neurological disorders. Clin. Chim. Acta 127:271-277.
58. LEVINE, S.M., S.G. LYNCH, C.N. OU et al. 1999. Ferritin, transferrin, and iron concentrations in the cerebrospinal fluid of multiple sclerosis patients. Brain Res. 821: 511-515.
59. BALLA, G., H.S. JACOB, J. BALLA et al. 1992. Ferritin: a cytoprotective antioxidant stratagem of endothelium. J. Biol. Chem. 267: 18148-18153.
60. HERBERT, V., S. SHAW, E. JAYATILLEKE & T. STOPLER-KASDAN. 1994. Most free-radical injury is iron-related: it is promoted by iron, hemin, holoferritin, and vitamin C, and inhibited by deferoxamine and apoferritin. Stem Cells 12: 289-303.
61. JUCKETT, M.B., J. BALLA, G. BALLA et al. 1995. Ferritin protects endothelial cells from oxidized low density lipoprotein in vitro. Am. J. Pathol. 147: 782-789.
62. VOGT, B.A., J. ALAM, A.J. CROATT et al. 1995. Acquired resistance to acute oxidative stress: possible role of heme oxygenase and ferritin. Lab. Invest. 72: 474-483.
63. MATZNER, Y., C. HERSHKO, A. POLLIACK et al. 1979. Suppressive effect of ferritin on in vitro lymphocyte function. Br. J. Haematol. 42: 345-353.
64. KEOWN, P. & B. DESCAMPS-LATSCHA. 1983. In vitro suppression of cell-mediated immunity by ferroproteins and ferric salts. Cell. Immunol. 80: 257-266.
65. MATZNER, Y., A.M. KONIJN, Z. SHLOMAI & B.H. BEN. 1985. Differential effect of isolated placental isoferritins on in vitro T-lymphocyte function. Br. J. Haematol. 59: 443-448.
66. HARADA, T., M. BABA, I. TORII & S. MORIKAWA. 1987. Ferritin selectively suppresses delayed-type hypersensitivity responses at induction or effector phase. Cell. Immunol. 109: 75-88.
67. HANN, H.W., M.W. STAHLHUT, S. LEE et al. 1989. Effects of isoferritins on human granulocytes. Cancer 12: 2492-2496.
68. WYLLIE, S., P. SEU & J.A. GOSS. 2002. The natural resistance-associated macrophage protein 1 SIc11a1 (formerly Nrampl) and iron metabolism in macrophages. Microb. Infect. 4: 351-359.
69. KOTZE, M.J., J.N. DE VILLIERS, R.N. ROONEY et al. 2001. Analysis of the NRAMP1 gene implicated in iron transport: association with multiple sclerosis and age effects. Blood Cells Mol. Dis. 27: 44-53.
70. YANG, Y.S., S.J. KIM, J.W. KIM & E.M. KOH. 2000. NRAMPI gene polymorphisms in patients with rheumatoid arthritis in Koreans. J. Korean Med. Sci. 15: 83-87.
71. RODRIGUEZ, M.R., M.F. GONZALEZ-ESCRIBANO, F. AGUILAR et al. 2002. Association of NRAMP1 promoter gene polymorphism with the susceptibility and radiological severity of rheumatoid arthritis. Tissue Antigens 59: 311-315.
72. BRETT, R. & M.G. RUMSBY. 1993. Evidence of free radical damage in the central nervous system of guinea-pigs at the prolonged acute and early relapse stages of chronic relapsing experimental allergic encephalomyelitis. Neurochem. Int. 23: 35-44.
73. LEVINE, S.M. & D.L. WETZEL. 1998. Chemical analysis of multiple sclerosis lesions by FT-IR microspectroscopy. Free Radical Biol. Med. 25: 33-41.
74. MACMICKING, J.D., D.O. WILLENBORG, M.J. WEIDEMANN et al. 1992. Elevated secretion of reactive nitrogen and oxygen intermediates by inflammatory leukocytes in hyperacute experimental autoimmune encephalomyelitis: enhancement by the soluble products of encephalitogenic T cells. J. Exp. Med. 176: 303-307.
75. RUULS, S.R., J. BAUER, K. SONTROP et al. 1995. Reactive oxygen species are involved in the pathogenesis of experimental allergic encephalomyelitis in Lewis rats. J. Neuroimmunol. 56: 207-217.
76. AQUINO, D.A., A.A. KLIPFEL, C.F. BROSNAN & W.T. NORTON. 1993. The 70-kDa heat shock cognate protein (HSC70) is a major constituent of the central nervous system and is up-regulated only at the mRNA level in acute experimental autoimmune encephalomyelitis. J. Neurochem. 61: 1340-1348.
77. DUZHAK, T., M.R. EMERSON, A. CHAKRABARTY et al. 2003. Analysis of protein induction in the CNS of SJL mice with experimental allergic encephalomyelitis by proteomic screening and immunohistochemistry. Cell. Mol. Biol. (Noisy-Le-Grand) 49: 723-732.
78. HONEGGER, C.G., W. KRENGER & H. LANGEMANN. 1989. Measurement of free radical scavengers in the spinal cord of rats with experimental autoimmune encephalomyelitis. Neurosci. Lett. 98: 327-332.
79. CALABRESE, V., G. SCAPAGNINI, A. RAVAGNA et al. 2003. Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem. Res. 28: 1321-1328.
80. CROSS, A.H., P.T. MANNING, M.K. STERN & T.P. MISKO. 1997. Evidence for the production of peroxynitrite in inflammatory CNS demyelination. J. Neuroimmunol. 80: 121-130.
81. VAN DER VEEN, R.C., D.R. HINTON, F. INCARDONNA & F.M. HOFMAN. 1997. Extensive peroxynitrite activity during progressive stages of central nervous system inflammation. J. Neuroimmunol. 77: 1-7.
82. LINK, H. 1998. The cytokine storm in multiple sclerosis. Mult. Scler. 4: 12-15.
83. NAVIKAS, V. & H. LINK. 1996. Review: cytokines and the pathogenesis of multiple sclerosis. J. Neurosci. Res. 45: 322-333.
84. RYTER, S.W. & R.M. TYRRELL. 2000. The heme synthesis and degradation pathways: role in oxidant sensitivity - heme oxygenase has both pro-and antioxidant properties. Free Radical Biol. Med. 28: 289-309.
85. ELBIRT, K.K. & H. L. BONKOVSKY. 1999. Heme oxygenase: recent advances in understanding its regulation and role. Proc. Assoc. Am. Physicians 111: 438-447.
86. ROUAULT, T. & R. KLAUSNER. 1997. Regulation of iron metabolism in eukaryotes. Curr. Top. Cell. Regul. 35: 1-19.
87. SCHNEIDER, B.D. & E.A. LEIBOLD. 2000. Regulation of mammalian iron homeostasis. Curr. Opin. Clin. Nutr. Metab. Care 3: 267-273.
88. LAVAUTE, T., S. SMITH, S. COOPERMAN et al. 2001. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat. Genet. 27: 209-214.
89. THOMPSON, K., S. MENZIES, M. MUCKENTHALER et al. 2003. Mouse brains deficient in H-ferritin have normal iron concentration, but a protein profile of iron deficiency and increased evidence of oxidative stress. J. Neurosci. Res. 71: 46-63.
90. EMERSON, M.R. & S.M. LEVINE. 2000. Heme oxygenase-1 and NADPH cytochrome P450 reductase expression in experimental allergic encephalomyelitis: an expanded view of the stress response. J. Neurochem. 75: 2555-2562.
91. SCHLUESENER, H.J. & K. SEID. 2000. Heme oxygenase-1 in lesions of rat experimental autoimmune encephalomyelitis and neuritis. J. Neuroimmunol. 110: 114-120.
92. GOLDMUNTZ, E.A., C.F. BROSNAN & W.T. NORTON. 1986. Prazosin treatment suppresses increased vascular permeability in both acute and passively transferred experimental autoimmune encephalomyelitis in the Lewis rat. J. Immunol. 137: 3444-3450.
93. CLAUDIO, L., Y. KRESS, J. FACTOR & C.F. BROSNAN. 1990. Mechanisms of edema formation in experimental autoimmune encephalomyelitis: the contribution of inflammatory cells. Am. J. Pathol. 137: 1033-1045.
94. PEDCHENKO, T.V. & S.M. LEVINE. 1998. Desferrioxamine suppresses experimental allergic encephalomyelitis induced by MBP in SJL mice. J. Neuroimmunol. 84: 188-197.
95. SARDANA, M.K. & A. KAPPAS. 1987. Dual control mechanism for heme oxygenase: tin(IV)-protoporphyrin potently inhibits enzyme activity while markedly increasing content of enzyme protein in liver. Proc. Natl. Acad. Sci. USA 84: 2464-2468.
96. MONSHOUWER, M., D. AGNELLO, P. GHEZZI & P. VILLA. 2000. Decrease in brain cytochrome P450 enzyme activities during infection and inflammation of the central nervous system. Neuroimmunomodulation 8: 142-147.
97. SEWERYNEK, E., M. ABE, R.J. REITER et al. 1995. Melatonin administration prevents lipopolysaccharide-induced oxidative damage in phenobarbital-treated animals. J. Cell. Biochem. 58: 436-444.
98. SCHOLZ, R.W., P.V. REDDY, A.D. LIKEN & C.C. REDDY. 1996. Inhibition of rat liver microsomal NADPH cytochrome P450 reductase by glutathione and glutathione disulfide. Biochem. Biophys. Res. Commun. 226: 475-480.
99. BOWERN, N., I.A. RAMSHAW, I.A. CLARK & P.C. DOHERTY. 1984. Inhibition of autoimmune neuropathological process by treatment with an iron-chelating agent. J. Exp. Med. 160: 1532-1543.
100. WILLENBORG, D.O., N.A. BOWERN, G. DANTA & P.C. DOHERTY. 1988. Inhibition of allergic encephalomyelitis by the iron chelating agent desferrioxamine: differential effect depending on type of sensitizing encephalitogen. J. Neuroimmunol. 17: 127-135.
101. WU, G.S., J. WALKER & N.A. RAO. 1993. Effect of deferoxamine on retinal lipid peroxidation in experimental uveitis. Invest. Ophthalmol. Visual Sci. 34: 3084-3089.
102. NORSTRAND, I.F. & W. CRAELIUS. 1989. A trial of deferoxamine (Desferal) in the treatment of multiple sclerosis: a pilot study. Clin. Trials J. 26: 365-369.
103. LYNCH, S.G., K. PETERS & S.M. LEVINE. 1996. Desferrioxamine in chronic progressive multiple sclerosis: a pilot study. Mult. Scler. 2: 157-160.
104. LYNCH, S.G., T. FONSECA & S.M. LEVINE. 2000. A multiple course trial of desferrioxamine in chronic progressive multiple sclerosis. Cell. Mol. Biol. (Noisy-Le-Grand) 46: 865-869.
105. MATSUOKA, Y., M. OKAZAKI & Y. KITAMURA. 1999. Induction of inducible heme oxygenase (HO-1) in the central nervous system: is HO-1 helpful or harmful? Neurotox. Res. 1: 113-117.
106. LIU, Y., B. ZHU, L. LUO et al. 2001. Heme oxygenase-1 plays an important protective role in experimental autoimmune encephalomyelitis. Neuroreport 12: 1841-1845.
107. STOCKER, R., Y. YAMAMOTO, A.F. MCDONAGH et al. 1987. Bilirubin is an antioxidant of possible physiological importance. Science 235: 1043-1046.
108. BARANANO, D.E., M. RAO, C.D. FERRIS & S.H. SNYDER. 2002. Biliverdin reductase: a major physiologic cytoprotectant. Proc. Natl. Acad. Sci. USA 99: 10693-10698.
109. OTTERBEIN, L.E., F.H. BACH, J. ALAM et al. 2000. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat. Med. 6: 422-428.
110. LIU, Y., B. ZHU, X. WANG et al. 2003. Bilirubin as a potent antioxidant suppresses experimental autoimmune encephalomyelitis: implications for the role of oxidative stress in the development of multiple sclerosis. J. Neuroimmunol. 139: 27-35.
111. RAINE, C.S., L.B. BARNETT, A. BROWN et al. 1980. Neuropathology of experimental allergic encephalomyelitis in inbred strains of mice. Lab. Invest. 43: 150-157.
112. WAGNER, K.R., Y. HUA, G.M. DE COURTEN-MYERS et al. 2000. Tin-mesoporphyrin, a potent heme oxygenase inhibitor, for treatment of intracerebral hemorrhage: in vivo and in vitro studies. Cell. Mol. Biol. (Noisy-Le-Grand) 46: 597-608.
113. PANIZZON, K.L., B.E. DWYER, R.N. NISHIMURA & R.A. WALLIS. 1996. Neuroprotection against CA1 injury with metalloporphyrins. Neuroreport 7: 662-666.
114. KADOYA, C., E.F. DOMINO, G.Y. YANG et al. 1995. Preischemic but not postischemic zinc protoporphyrin treatment reduces infarct size and edema accumulation after temporary focal cerebral ischemia in rats. Stroke 26: 1035-1038.
115. LUCCHINETTI, C., W. BRUCK, J. PARISI et al. 2000. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47: 707-717.
116. ADAMS, C.W., R.N. POSTON, S.J. BUK et al. 1985. Inflammatory vasculitis in multiple sclerosis. J. Neurol. Sci. 69: 269-283.
117. LEVINE, S.M., S. MAITI, M.R. EMERSON & T.V. PEDCHENKO. 2002. Apoferritin attenuates experimental allergic encephalomyelitis in SJL mice. Dev. Neurosci. 24: 177-183.
118. REIF, D.W. & R.D. SIMMONS. 1990. Nitric oxide mediates iron release from ferritin. Arch. Biochem. Biophys. 283: 537-541.
119. REIF, D.W. 1992. Ferritin as a source of iron for oxidative damage. Free Radical Biol. Med. 12: 417-427.
120. HOOPER, D.C., S. SPITSIN, R.B. KEAN et al. 1998. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc. Natl. Acad. Sci. USA 95: 675-680.
121. MARRACCI, G.H., R.E. JONES, G.P. MCKEON & D.N. BOURDETTE. 2002. Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis. J. Neuroimmunol. 131: 104-114.
122. HANSEN, L.A., D.O. WILLENBORG & W.B. COWDEN. 1995. Suppression of hyperacute and passively transferred experimental autoimmune encephalomyelitis by the antioxidant, butylated hydroxyanisole. J. Neuroimmunol. 62: 69-77.
123. MALFROY, B., S.R. DOCTROW, P.L. ORR et al. 1997. Prevention and suppression of autoimmune encephalomyelitis by EUK-8, a synthetic catalytic scavenger of oxygen-reactive metabolites. Cell. Immunol. 177: 62-68.
124. KANG, J.C., M. AHN, Y.S. KIM et al. 2001. Melatonin ameliorates autoimmune encephalomyelitis through suppression of intercellular adhesion molecule-1. J. Vet. Sci. 2: 85-89.
125. LEHMANN, D., D. KARUSSIS, R. MISRACHI-KOLL et al. 1994. Oral administration of the oxidant-scavenger N-acetyl-L-cysteine inhibits acute experimental autoimmune encephalomyelitis. J. Neuroimmunol. 50: 35-42.
126. MOHAMED, A., A. SHOKER, F. BENDJELLOUL et al. 2003. Improvement of experimental allergic encephalomyelitis (EAE) by thymoquinone, an oxidative stress inhibitor. Biomed. Sci. Instrum. 39: 440-445.